Drug Trial Radar · NCT06935370
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
4,200
Planned (sponsor's estimate)
Start
May 20, 2025
Primary completion
Feb 4, 2029
Study completion Feb 22, 2029
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Apr 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they have been diagnosed with chronic HF at least 3 months before they start on the study. The purpose of this study is to find out whether a medicine called vicadrostat, in combination with another medicine called empagliflozin, helps people with chronic heart failure. In this study, participants are put into 2 groups randomly. Participants have an equal chance of being in either group. One group takes vicadrostat/empagliflozin tablets, and the other group takes placebo/empagliflozin tablets. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants take the study medicines as tablets once a day for between about 6 months and about 3.5 years. During this time, they can continue their regular treatment for heart failure. Participants can stay in the study as long as they benefit from treatment and can tolerate it, for a maximum of about 3.5 years. During this time, they visit the study site regularly. The exact number of visits is different for each participant, depending on how long they stay in the study. The study staff may also contact the participants by phone for some visits. Participants also regularly answer questions about their well-being. The doctors document when participants experience worsening of their heart failure symptoms, go to hospital due to heart failure or die during the study. The time until these events are observed is compared between the two treatment groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Heart Failure
Interventions
vicadrostatDrug
vicadrostat
empagliflozinDrug
empagliflozin
PlaceboDrug
Placebo matching vicadrostat
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first event of Cardiovascular (CV) death, or Hospitalisation for heart failure (HHF), or Urgent heart failure (HF) visitTime frame: up to 43 months
Locations
596 sites in 29 countries. Site status is shown where the registry gives one.
Cure Clinical Research
Beverly Hills, California · Suspended
Valley Clinical Trials, Inc.
Covina, California · Recruiting
North Coast Cardiology
Encinitas, California · Not yet recruiting
Merced Vein and Vascular Center
Merced, California · Recruiting
Radin Cardiovascular Medical Group
Newport Beach, California · Recruiting
Amicis Research Center - Nordhoff
Northridge, California · Terminated
University of California San Diego
San Diego, California · Not yet recruiting
Paradigm Clinical Research - San Diego
San Diego, California · Recruiting
Amicis Research Corporate
Santa Clarita, California · Terminated
Care Access Research
Thousand Oaks, California · Recruiting
Bay Area Cardiology
Brandon, Florida · Suspended
Cardiology Associates Research Co.
Daytona Beach, Florida · Recruiting
Suncoast Research Associates, LLC
Doral, Florida · Recruiting
Malcom Randall VA Medical Center
Gainesville, Florida · Recruiting
Velocity Clinical Research-Hallandale Beach-67888
Hallandale, Florida · Recruiting
University of Florida
Jacksonville, Florida · Recruiting
East Coast Institute For Research, LLC
Jacksonville, Florida · Recruiting
Jacksonville Center for Clinical Research
Jacksonville, Florida · Recruiting
University of Miami - Miller School of Medicine
Miami, Florida · Recruiting
Infinite Clinical Research Inc
Miami, Florida · Recruiting
Inpatient Research Clinic, LLC
Miami Lakes, Florida · Recruiting
Innovation Medical Research Center
Palmetto Bay, Florida · Recruiting
Peace River Cardiovascular Center
Port Charlotte, Florida · Recruiting
St. Johns Center for Clinical Research
Saint Augustine, Florida · Recruiting
University of South Florida
Tampa, Florida · Recruiting
Cardiology Partners Clinical Research Institute
Wellington, Florida · Recruiting
Cozy Research LLC
Wesley Chapel, Florida · Recruiting
Flourish Research
Winter Park, Florida · Recruiting
Atlanta Clinical Research Centers
Atlanta, Georgia · Recruiting
NSC Research Inc
Johns Creek, Georgia · Recruiting
Northwest Heart Clinical Research, LLC
Arlington Heights, Illinois · Not yet recruiting
Chicago Medical Research
Hazel Crest, Illinois · Recruiting
Clinical Investigation Specialists, Inc.
Libertyville, Illinois · Recruiting
AMR Park Ridge
Park Ridge, Illinois · Recruiting
Springfield Clinic
Springfield, Illinois · Recruiting
Midwest Cardiovascular Research and Education Foundation
Elkhart, Indiana · Recruiting
St. Francis Medical Group-Indiana Heart Physicians, Inc
Indianapolis, Indiana · Recruiting
Indiana Medical Research Institute
Merrillville, Indiana · Recruiting
Cardiovascular Research of Northwest Indiana, LLC
Munster, Indiana · Recruiting
Reid Hospital
Richmond, Indiana · Recruiting
Showing 40 of 596 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.